Welgus Howard G. sold $133K of ARQT

Welgus Howard G. sold 4,728 shares of Arcutis Biotherapeutics, Inc. (ARQT) at $28.16 ($0.13M total) on 2026-11-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Welgus Howard G.
Published Nov 18, 2026, 9:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 9:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARQT
Neutral
high confidence
Mentioned
$ARQT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARQTNeutralLow
01

Why it matters

A director’s open-market sale under a pre-arranged 10b5-1 plan is typically treated as routine compliance rather than a direct fundamental catalyst.

02

Market read

Traders may monitor insider-flow sentiment, but the 10b5-1 structure reduces the likelihood of a material price catalyst.

03

What to watch

The article provides only the sale details; it does not state whether there were concurrent buys, changes in business outlook, or broader insider activity trends.

Relevance 3/10Novelty 3/10Timing: after-hours filing date, for positioning around insider-flow sentiment

Background

The article is a SEC Form 4 insider transaction report for Arcutis Biotherapeutics, Inc. (ARQT).

Company-level read

Ticker impact

$ARQTNeutralHigh confidence
Context

Director Welgus Howard G. sold 4,728 shares in an open-market transaction on 2026-11-16 under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited, with any reaction more sentiment-driven than fundamental.

Evidence & confidence

The filing is a Form 4 insider sale with 10b5-1 pre-arrangement, and it does not include new operating, regulatory, or financial guidance.

Market effects

No clear sector read-through from a single director 10b5-1 sale.

None.

None.

Counterpoint

Even with 10b5-1, repeated insider selling can be interpreted as reduced confidence, especially if paired with other negative signals not mentioned here.

Key entities

  • Arcutis Biotherapeutics, Inc.

    US-listed biotherapeutics company subject of the Form 4 insider sale disclosure.

  • Welgus Howard G.

    Director who sold 4,728 shares on 2026-11-16 under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ARQTHighAI 8/10

Arcutis reports trial data on infant eczema treatment candidate

Arcutis Biotherapeutics (ARQT) presented INTEGUMENT-INFANT trial data for ZORYVE cream 0.05% in treating infant atopic dermatitis. The study showed no serious adverse events, with 66.7% of infants reporting itch improvement within 4 hours. The cream is approved for children 2-5 years and is under FDA review for infants 3-24 months, with a decision expected by February 23, 2027.

$ARQTMed

Arcutis (ARQT) Q3 2026 Earnings Call Transcript

Arcutis Biotherapeutics (ARQT) reported Q3 2026 revenue of $143.9M, up 45% YoY, driven by ZORYVE franchise growth. Full-year revenue guidance raised to $535M-$545M. Net income was $8.8M, with cash and securities at $259.8M. The company plans to invest in commercial initiatives for 2027 growth, focusing on dermatology and primary care.

$ARQTMedAI 8/10

TD Cowen raises Arcutis stock price target on Zoryve momentum

TD Cowen raised its price target for Arcutis Biotherapeutics (ARQT) to $40 from $35, citing strong Zoryve sales of $144M and raised 2026 guidance. Revenue grew 11% quarter-over-quarter and 45% year-over-year, with a 91% gross profit margin. The stock trades near its 52-week high at $34.05. Arcutis reported Q3 2026 revenue of $143.9M, beating estimates, but missed profit expectations.